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Introduction 
FK 506 (Prograt) is a novel macrolide antibiotic isolated from the soil fungus 
Streptomyces tsukubaensis [24]. Although it is totally distinct in molecular struc-
ture from cyclosporin (CsA) (Sandimmune), a cyclic endecapeptide extracted 
from the fungus Tolypocladium inflatum (Fig. 1), the two drugs share a remark-
ably similar, selective inhibitory action on the activation and proliferation of 
CD4 + T helper (TH) lymphocytes [25, 41,50,51,56]. These cells play an essential, 
central role both in antigen recognition and as the sources of soluble, hormone-
like mediators (cytokines) of the cascade of events leading to the expression of 
immune reactivity. By inhibiting the activation of CD4 + TH cells, FK 506, like 
CsA, exerts a wide-range of immunosuppressive activities. It is recognized that 
both drugs prolong solid-organ allograft survival in experimental animals and in 
man. FK 506, however, is considerably more powerful as an antilymphocytic 
agent than esA, as evidenced by the superior potency of the former drug in 
inhibiting antigen-driven T cell activation, cytokine production and lymphocyte 
proliferation in vitro [50]. Moreover, the systemic levels of FK 506 required to 
induce and maintain immune suppression are approximately 100-fold lower than 
are the blood levels of esA to achieve the same effect. The immunosuppressive 
efficacy of esA in man (in renal transplant recipients and patients receiving bone 
marrow transplants) was first reported in 1978; in 1989, the first account of the 
ability of FK 506 to prevent or reverse organ allograft rejection was published 
[44]. Data obtained over the last 3 years provide good clinical evidence that 
FK 506 exhibits a narrower range of side effects than does CsA and that, as 
compared with CsA, FK 506 has greater steroid-sparing activity [45, 46]. Whilst 
the potential benefits of FK 506 for the prophylaxis and reversal of organ allo-
graft rejection (in particular liver transplant rejection) are becoming recognized, 
the value of the drug in the treatment of autoimmune disorders is now also 
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FK506 CYCLOSPORIN A 
Fig. 1. The molecular structure of the immunosuppressive macrolide FK 506 (mol. wt. 822 
daltons) and of the less powerful, but similarly acting cyclic endecapeptide cyclosporin A 
(mol. wt. 1203 daltons) 
beginning to be assessed. In this article (1) a rationale for the use of FK 506 in 
autoimmune disease, (2) a description of its molecular action and immunosup-
pressive activities, (3) a consideration of the biological and pharmacological 
properties of FK 506, (4) a review of its capacity to inhibit a wide variety of 
experimental autoimmune disorders, and (5) a report on the early clinical experi-
ence with FK 506 in the clinical management of a panoply of autoimmune disease 
seen at the University of Pittsburgh Medical Center (UPMC) will be presented. 
Moreover, a brief outline of laboratory investigations utilized to monitor the 
status of T lymphocytes in these patients and a discussion of the side effects of 
FK 506 will be presented. Throughout, we shall draw upon comparisons between 
FK 506 and CsA which have been documented in the literature. 
Rationale for the use of FK 506 in autoimmune diseases 
The role of T cells in autoimmunity 
The therapeutic use of FK 506 in the treatment of autoimmune disease is based 
on the premise that all of these disorders are T cell driven [39]. It is, therefore, 
important to examine the evidence that activated CD4 + TH cells and their cy-
tokine products are important both in the induction and maintenance of various 
diseases such as psoriasis, uveitis, insulin-dependent type-l diabetes, chronic ac-
tive hepatitis-autoimmune (CAR-A), rheumatoid arthritis and multiple sclerosis 
- diseases that are currently being treated with FK 506. In uveitis [11], type-l 
diabetes [6], multiple sclerosis [16] and psoriasis [3] for example, T cells are 
believed to play an important pathogenic role. Much of the evidence to support 
this view comes from studies in experimental animal models and from in vitro 
investigations of the adverse or destructive interactions between T cells, antigen-
stimulated cytokines and the target tissue affected by the disease process. In the 
autoimmune liver diseases [26], CAH-A and primary biliary cirrhosis (PBC), and 
in rheumatoid arthritis [9], there is abundant evidence for the involvement of T 
cells in the pathogenesis of each disease and, therefore, a rationale for the use of 
FK 506 in each exists. In recent years the therapeutic efficacy of CsA in uveitis, 
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Table 1. Possible mechanisms of autoimmune diseases and predicted responses to FK 506" 
Disease Implicated mechanism b Predicted efficacy 
of FK 506" 
Autoimmune uveitis T cells +++ 
Type-l diabetes T cells(Abs C +++ 
Psoriasis T cells/non-immunological +++ 
Chronic active hepatitis T cells and cytotoxic Abs + 
(autoimmune) 
Primary biliary cirrhosis T cells +Abs ++ 
Rheumatoid arthritis T cells + Abs? ++ 
SLE Abs + 
Myasthenia gravis Abs ± 
Immune cytopcnias Abs ± 
Nephrotic syndrome T cells/non-immunological? + 
• Dependent on timing of instigation of therapy in relation to disease progression 
b Oversimplification for purposes of concept formation 
C Antibodies (Abs) to insulin and islet cells believed to be epiphenomena 
psoriasis, PBC, CAR-A, and rheumatoid arthritis has been demonstrated [52]. 
Moreover, CsA has been shown to alter the natural history oftype-l diabetes [4]. 
The drug has not, however, made a significant impact upon the clinical manage-
ment of patients with most of these diseases. 
In autoimmune diseases such as systemic lupus erythematosus (SLE) or the 
nephrotic syndrome, the rationale for the use ofCsA or FK 506 is less clear. Thus, 
in SLE, humoral immunity appears to be more important than cellular immunity 
in the pathogenesis of the disease, and in idiopathic nephrotic syndrome the 
pathogenic mechanisms responsible for the disease process are far from clear. 
Nevertheless, in nephrotic syndrome, T cell dysfunction, recruitment of B cells, 
immunoglobulin deposition within the kidney and a central role for lymphokines 
have been implicated by various authors [7,8, 18, 54]. Moreover, CsA has been 
shown to be very effective in the steroid-sensitive nephrotic syndrome, although 
less so in steroid-resistant patients [52]. 
A spectrum of autoimmune disorders is shown in Table 1. The predicted 
efficacy of FK 506 in their treatment is based on the assumption that the role of 
T cells in these various disease processes is central, and also on experience in 
animal models of these diseases with either CsA or FK 506. Account is also taken 
of clinical experience with CsA in these autoimmune disorders. 
Evidence that autoimmune diseases are T cell driven 
There is a large body of additional experimental data which provides supportive 
evidence to the thesis that autoimmune diseases are driven by T cells and their 
cytokine products. In addition to the proven efficacy of CsA or FK 506 in many 
experimental autoimmune diseases, antibodies directed against CD4 + T cells or 
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against the interleukin 2 receptor (IL-2R; expressed on activated T cells) have 
been shown to be effective therapeutic agents in these animal models. When 
stimulated with appropriate antigen or monoclonal antibody, T cell clones 
derived from lesional tissue or peripheral blood secrete cytokines which effect the 
pathological changes observed in target tissue (e.g., fibroblasts in scleroderma, 
keratinocytes in psoriasis or islet cells in type-l diabetes) that are relevant to the 
disease process observed in vivo. Such antigen-stimulated T cell clones can induce 
disease when transferred to healthy recipients (e.g., induction of type-l diabetes, 
experimental arthritis or allergic encephalomyelitis). Furthermore, in many ex-
perimental models of autoimmunity, it can be shown that neonatal thymectomy 
has a pronounced beneficial effect in preventing development of the disease. For 
references and discussion see [40]. 
The central role of CD4+ T cells 
There are two general prerequisites for the induction of autoimmunity. First, 
self-reactive T cells must be present in the immunological repertoire and second, 
self antigen must be presented in conjunction with major histocompatibility com-
plex (MHC) class II determinants on a competent, antigen-presenting cell (APC) 
(Fig. 2). IL-2 is produced in response to the signal generated by processed antigen 
presented on the APC surface in association with MHC class II molecules inter-
acting with the antigen-specific T cell receptor (TCR). Secreted IL-2 interacts 
with specific cell surface IL-2R to induce clonal T lymphocyte proliferation. The 
CD4 + T cell population contains subsets (THI and TH2 cells), which have been 
characterized in murine systems and have been shown to differ in the mixture of 
cytokines that they secrete [34]. Thus, THI cells can be shown to be the source of 
IL-2 and interferon (IFN)-y and promote cell-mediated immune responses, whilst 
TH2 cells secrete IL-4, IL-5, IL-6 and IL-l0 which direct the differentiation of 
(self-reactive) B cells. It appears likely that cross-regulation of T cell function 
exists between the THI and TH2 cell populations and that this effect is modulated 
by cytokines (see Fig. 2). The cytokine products of activated CD4 + T cells direct 
the production and recruitment of effectors, which include MHC class I-restricted 
cytotoxic (CD8 +) T cells that directly attack antigen-bearing cells (such as islet 
cells in type-l diabetes or thyrocytes in experimental autoimmune thyroiditis). 
Effectors also include the lymphokines tumor necrosis factor (TNF)-IX and -f3, 
which damage surrounding cells, and IFN-y, which increases production of nat-
ural killer (NK) cells and increases MHC class II expression both on epithelial 
and endothelial cells. This in turn may promote localization of CD4 + T cells. 
Up-regulation of adhesion molecule expression on vascular endothelium by IFN-
y may also promote the homing of lymphocytes and neutrophils to affected 
tissues. 
In a number of autoimmune diseases (e.g., SLE), the primary pathology is 
attributable to antigen-antibody complexes which localize in capillary beds, acti-
vate complement and attract leukocytes that inflict tissue damage. In another 
important group of autoimmune diseases, autoantibodies directed against physi-
ological receptors on the cell surface are responsible for disease activity. Such 
antibodies include autoantibodies directed against the acetylcholine receptor in 
myasthenia gravis and autoantibodies to the thyroid-stimulating hormone recep-
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Fig. 2. The central role of CD4 + 
T helper (TH) lymphocytes and 
their cytokine products in the gen-
eration of effector mechanisms in 
autoimmunity. Additional mecha-
nisms (not shown) include cy-
tokine-driven activation (via IFN-
y) of macrophages leading to 
tissue lysis and via (IL-2) of natu-
ral killer cells and (via IL-6) of 
vascular endothelium. Most au-
toimmune diseases are probably a 
combination of all of these patho-
genetic mechanisms. The site of 
action of FK 506 on the early 
event of antigen-induced CD4 + 
TH cell activation is depicted by 
the open arrow 
tor in Graves' disease. Most autoimmune diseases, however, are probably caused 
by a combination of various cell, antibody, complement and cytokine-mediated 
pathogenic mechanisms. 
Given the foregoing considerations, it is likely that FK 506 will have a greater 
efficacy in the diseases in which T cells have been shown to have a major role in 
inducing and maintaining disease pathology than will CsA (Table 1). 
The molecular action of FK 506 
The molecular actions of FK 506 and esA have recently been reviewed by 
Schreiber and Crabtree [42] and Sigal and Dumont [43]. FK 506 inhibits CD4 + T 
cell activation mediated by the TCR-CD3 complex and via the cell surface mol-
ecule, CD2. IL-2 production, T cell proliferation, and apoptosis (programmed 
cell death) are all sensitive to FK 506, as they are to CsA. Inhibition of T cell 
activation is dependent on exposure to the drug within the first few hours of 
antigenic stimulation. Effective concentrations ofFK 506 are 100-fold lower than 
those of CsA. FK 506 does not appear to directly affect the function of accessory 
cells. Functions of other leukocytes, however, may be influenced by FK506. Thus 
FK 506 (like CsA) inhibits proinflammatory mediator release from human 
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basophils and rat mast cells, as well as the transcription of several cytokine genes, 
including IL-3 and IL-5. These latter actions may contribute to some of the drug's 
therapeutic anti-inflammatory effects. 
In T cells FK 506 acts at a step distal to the cell membrane receptors and 
second messengers but proximal to the transcriptional activation of early genes. 
Both FK 506 and CsA strongly and specifically inhibit the expression of early 
activation genes encoding IL-2, IL-3, IL-4, IFN-y, granulocyte/macrophage-
colony-stimulating factor and c-myc [51]. Two subsets of murine CD4 + T cells 
(THI and TH2) have been identified on the basis of the cytokines they secrete and 
their functional profiles [34]. There is some evidence that such functional TH 
subsets may also exist in humans. THI cells produce IL-2, IFN-y, and TNF-f3. TH2 
cells secrete IL-4, IL-5, and IL-10, but not IL-2 or IFN-y.1t appears that in vitro, 
at least, FK 506 may spare IL-10 gene transcription by TH2 cells, while inhibiting 
concomitant IL-4 mRNA production [53]. Thus, differential interference with 
cytokine gene transcription and cross-regulation of IL-2 and IFN-y production 
by THI cells may be an important mechanism whereby FK 506 acts to inhibit 
induction of immune reactivity and maintain immunosuppression. 
Both FK 506 and CsA bind to specific, intracellular cytosolic receptors or 
"immunophilins," designated FK 506-binding protein (FKBP) and cyclophilin, 
respectively [42, 43]. Both molecules exist in a number of isoforms. These "im-
munophilins" are peptidyl-prolyl cis-trans isomerases (PPIases) which catalyze 
cis-trans isomerization of Ala-Pro bonds in oligopeptides and accelerate protein 
folding. Binding of each drug to its respective immunophilin inhibits isomerase 
activity. Recent data indicate that inhibition of isomerase activity is not the 
critical site of action of either FK 506 or CsA. Instead, the immunosuppressive 
effect of both drugs results from the formation of active complexes between the 
drug and its respective isomerase. Complexes of FK 506 and FKBP and of CsA 
and cyclophilin bind specifically to three polypeptides, calmodulin, and the two 
subunits of a Ca2 + activated, Ser-Thr protein phosphate calcineurin [27]. In each 
instance, FK 506 or CsA promotes the interaction of the normally non-interact-
ing immunophilin and calcineurin, resulting in inhibition of the phosphatase 
activity of calcineurin. Neither FK 506, FKBP, CsA, nor cyclophilin alone in-
hibits the enzymic activity of calcineurin. 
A further important property of the drug-immunophilin complexes is that 
they block Ca2 + -dependent assembly of the IL-2 gene transcription activator 
nuclear factor of activated T cells (NF-AT). This is achieved by inhibition of the 
translocation of the preexisting cytoplasmic component of NF-AT (NF-ATc) 
from the cytoplasm to the nucleus [10]. The nuclear component ofNF-AT (NF-
ATn), which is induced by signals from the TCR, is transcriptionally inactive in 
all cells other than activated T lymphocytes. Its appearance is not blocked by 
FK 506 or CsA.1t appears, however, that FK 506 and CsA block the calcineurin-
mediated dephosphorylation of NF -ATc which is required for its translocation to 
the nucleus. In the absence of both NF-ATc and NF-ATn transcriptional activa-
tion of the IL-2 gene and other genes is suppressed. For further details of the 
molecular action of FK 506 and CsA the reader is referred to the recent literature 
[10,27,42,43]. 
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Biological and pharmacological properties of FK 506 in comparison to CsA 
Although quite distinct in molecular structure, FK 506 and CsA share many 
biological and pharmacological properties (e.g., binding to intracellular im-
munophilins, selective interference with CD4 + T cell function, rate of systemic 
absorption, plasma half-lives, etc.). The similar properties of the two immunosup-
pressants are listed in Table 2. Properties of FK 506 and CsA which are known 
to differ are shown in Table 3. Of special significance, in relation to the potential 
value of the drugs in autoimmune diseases, is the superior capacity of FK 506, 
compared with CsA, to reverse cell-mediated immunity (e.g., allograft rejection 
or graft-versus-host disease). 
Table 2. Biological and pharmacological properties of FK 506 and cyc1osporin A (CsA): simi-
larities 
- Molecular action and antilymphocytic activity (similar actions on CD4 + T cells and cytokine 
generation) 
- Interference with T cell maturation (reversible) 
- Immunosuppressive and toxic effects related mechanistically 
- Inhibition of mast cell degranulation 
- Binding to intracellular immunophilin (CsA to cyc1ophilin; FK 506 to FK BP) 
- Inhibition of apoptosis 
- Metabolism in liver (cyt P450 mixed function oxidases) 
- Metabolites are excreted into bile 
- Wide tissue distribution (lipophilic) 
- Plasma half-lives (CsA 5-12 h; FK 5064-14 h) 
- Absorption (CsA 2-4 h; FK 506 0.5-4 h) 
- Not excreted in urine «2%) 
- Metabolites ineffective 
- Oral absorption (CsA 30%; FK 506 35%) 
- Drug interactions (e.g., erythromycin; ketoconazole) 
- Hepatotrophic 
- Predominant blood distribution in red blood cells 
FK BP, FK S06-binding protein 
Table 3. Biological and pharmacological properties of FK 506 and CsA: differences 
- Molecular structure 
- Immunophilins distinct 
- Therapeutic level (CsA Ilg ml; FK 506: ng/ml) 
- CsA absorption (but not that of FK 506) dependent on bile flow 
- FK 506 (but not CsA) reverses cell-mediated immunity (GVHD, allograft rejection) 
- Drug interactions: no change of FK level with the combination of calcium channel blockers 
- Hypogonadism (male especially, and female) (CsA) 
- Antilymphocytic effects of FK 506 less easily reversed (in vitro) 
GVHD, Graft-versus-host disease 
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The influence of FK 506 on experimental autoimmune diseases 
FK 506 is effective in inhibiting a wide variety of experimental autoimmune 
disorders in rodents and in larger laboratory animals (Table 4). The autoimmune 
diseases in which the immunosuppressive efficacy of FK 506 has been proved 
include uveitis, type-1 diabetes, thyroiditis, autoimmune renal disorders, experi-
Table 4. Experimental autoimmune diseases suppressed by FK 506 
Disorder 
Arthritis (type II 
collagen-induced) 
Type-l diabetes 
Uveoretinitis 
Thyroiditis 
Lupus (SLE) 
Glomerulonephritis 
(Nephrotoxic antiserum 
nephritis) 
Heymann nephritis 
Allergic encephalomyelitis 
Autoimmune myocarditis 
Experimental allergic 
contact dermatitis 
Murine (coxsackie B3) 
myocarditis 
Species 
Rat (Lewis) 
Rat (outbred) 
Mouse (DBA/l) 
NOD mouse 
Cyclophosphamide-
treated NOD mouse 
BB rat 
BB rat 
Rat (Lewis) 
Rhesus & cynomolgus 
monkeys 
Rat (PVG) 
MRL/lpr/lpr mouse 
NZB/NZW Fl mouse 
Rat (Wistar) 
Rat (Wi star) 
Rat (Wistar) 
Rat (Lewis) 
Rat (Lewis) 
Rat (Lewis) 
Farm pig 
Mice (C3H/He) 
" Suppresses induction of disease 
h Partially effective during efferent phase of response 
C On day of immunization 
d Administered daily from 27 -120 days of age 
e Effective only in induction phase 
f Administered from 3 weeks after immunization 
FK 506 dose 
(mg/kg per day 
unless specified) 
0.32 a .b 
2.5' 
2.0 
2.0 mg/kg per 48 h' 
0.2, 1. 2 
1.0' 
25 Ilg i.m. d 
1.0'" 
O.Sf 
2.0 8 
2mgh 
2.5 mg/kg per 48 hi 
0.3mgi 
0.64 
0.64" 
1.0 k 
1.0 j 
0,1 0.32. 1 
0.04, 0.4% topical 
2.5 
g Administered for 3 weeks following induction of disease 
h Administered from 8 weeks of age 
From time of immunization 
j Administered 5 days per week after immunization 
k Administered from day 0-13 or 56-69 
[Reference] 
[20] 
[2] 
[48] 
[32] 
[5] 
[35] 
[36] 
[23] 
[12] 
[49] 
[55] 
[47] 
[15] 
[38] 
[38] 
[28] 
[19] 
[14] 
[31] 
[17] 
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Fig. 3 a-d. Prevention of the development of experimental autoimmune thyroiditis and insulitis 
in thymectomized, x·irradiated female PVG/c rats treated with FK 506 starting after serological 
evidence of autoantibody (anti-thyroglobulin) production. a Lymphocytic thyroiditis with oblit-
eration of thyroid follicles in untreated, control animals; b inhibition of thyroiditis by FK 506; 
c severe insulitis, which was evident in 30% of untreated disease control animals, and d preven-
tion of insuJitis by FK 506 
mental allergic encephalomyelitis (a correlate of multiple sclerosis) and autoim-
mune myocarditis. An example of the inhibitory effect of FK 506 on experimental 
autoimmune disease is shown in Fig. 3. PVG/c female rats which have been 
neonatally thymectomized and sublethally irradiated subsequently develop au-
toimmune thyroiditis. The development of the disease is inhibited by a 3-week 
course of FK 506 starting after demonstration of serological evidence of autoan-
tibody (anti-thyroglobulin antibody) production. Some untreated disease control 
animals also develop insulitis. This can be prevented by FK 506 administration. 
Early clinical experience with FK 506 at the University of Pittsburgh (Table 5) 
Primary sclerosing cholangitis 
A total of 11 cases of primary sclerosing cholangitis (PSC) have been treated with 
FK 506 in the autoimmune clinic at UPMC. Most of these cases have also had 
ulcerative colitis. A few have either had Crohn's colitis (n=4) or no colonic 
disease at all (n = 4). The biochemical responses of a who responded patient with 
PSC and ulcerative colitis to FK 506 therapy is shown in Fig. 4. A dramatic 
decline in total bilirubin and alkaline phosphatase occurred early, with a later 
reduction in the ALT and AST levels. 
Primary biliary cirrhosis 
A total of 16 patients with PBC have been treated with FK 506 in the autoimmune 
clinic of UPMC. The majority of these cases have been women. Most but not all 
have shown a response to FK 506 therapy as illustrated in Fig. 5, with a marked 
reduction in the serum bilirubin and alkaline phosphatase levels and with modest 
reductions into the normal range for serum alanine aminotransferase (ALT) and 
aspartate aminotransferase (AST) levels. 
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Table 5. Protocols for treatment of autoimmune diseases utilizing FK 506 at the University of 
Pittsburgh Medical Center (September 1992)" 
Eye and ear diseases 
Uveitis (2); scleritis (1) 
Ocular cicatrical pemphigoid (1) 
Autoimmune inner ear disease (4) 
Neurological 
Multiple sclerosis (57); amyotrophic lateral sclerosis (4) 
Renal 
Nephrotic syndrome (32) 
Gastrointestinal 
Ulcerative colitis (19) 
Crohn's disease (17) 
Chronic active hepatitis (autoimmune) (21) 
Primary sclerosing cholangitis (11) 
Primary biliary cirrhosis (16) 
Sprue (4) 
Skin 
Psoriasis (16) 
Pyoderma gangrenosum (6) 
Epidermolysis bullosum (1) 
Endocrine 
New onset type-l diabetes (11) 
Collagen vascular disease/vasculitis 
Beh~etDs disease (2) 
Scleroderma (5) 
Polymyositis/dermatomyositis (2) 
Wegener's granulomatosis (1) 
" Figures in parentheses denote numbers of patients being treated 
Autoimmune chronic active hepatitis 
A total of 21 cases of autoimmune chronic active hepatitis have been treated with 
FK 506 at UPMC. The majority have been women. Half had failed to respond to 
glucocorticoids alone or used in combination with azathioprine. One failed with 
CsA. In responders, elevated bilirubin and transaminase levels declined into the 
normal range with the institution of FK 506 (Fig. 6). Of the three types of hepatic 
disease that have been treated with FK 506, this group with CAH-A appears to 
respond best and most consistently. Patients with well-established, advanced 
cirrhosis are unlikely to respond as shown in Figs. 4-6. 
Crohn's disease 
A total of 17 patients with Crohn's disease have been treated with FK 506 at 
UPMC. Most have had complicated diseases, involving the colon or colon and 
small bowel with multiple perianal, vaginal, vesicular or cutaneous fistulae. 
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Fig.4. Biochemical responses (serum total bilirubin, alkaline phosphatase, ALT and AST levels) 
in a representative responder with primary sclerosis cholangitis (PSC) treated wtih FK 506 
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FK 506 treatment has, in all cases, been followed by a reduction in the amount 
of drainage and in most cases, by drying up of fistulous tracts. Enteric disease has 
not been eradicated under FK 506 but the complications have resolved such that 
surgical repair has become possible. It may well be that the ideal role for FK 506 
in this disease process may be in the preoperative management of cases. Often, an 
apparently inoperable case can be converted to an easily resectable case with the 
use of FK 506. Moreover, its use preoperatively enables the patient to go to 
surgery without the use of steroids that complicate healing and foster infection in 
the early post-operative period. 
Ulcerative colitis 
A total of 19 cases of ulcerative colitis have been treated with FK 506. Of these 
11 also have PSC, while 6 have ulcerative colitis without confounding PSc. The 
response of ulcerative colitis to FK 506 treatment has not been particularly im-
pressive. Nonetheless, it has enabled several of the non-PSC cases to stabilize their 
disease activity and then to undergo one or another form of surgery to treat a 
complication of the disease, usually a colonic stricture. The role of FK 506 in the 
management of ulcerative colitis appears to be less clear than its role in the 
treatment of Crohn's disease and related complications. 
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Sprue (celiac disease) 
A total of four patients with sprue documented by (i) the presence of gluten 
sensitivity, (ii) an atrophic small bowel mucosa on intestinal biopsy, and (iii) the 
presence of detectable reticulum antibodies have been treated with FK 506. One 
of these four cases had failed gluten withdrawal and had required total parenteral 
nutrition (TPN) for several years prior to the use of FK 506. All patients are able 
to eat a normal diet containing gluten without the development of symptoms 
while taking FK 506. o-Xylose absorption has improved in all four subjects but 
remains abnormal in the single patient who had required TPN for several years 
prior to the institution of FK 506. On FK 506 treatment the appearance of 
intestinal biopsies has improved in all cases; the improvement has been rather 
small, however, in the single case that had required TPN to maintain her nutri-
tional status prior to the use of FK 506. Despite still requiring TPN, the extra-
intestinal consequences of her disease (hypogonadism, cheilitis, hair loss, fatigue 
and seizures related to hypocalcemia) have all resolved or improved while on 
FK 506. 
Uveitis/scleritis (n=3) 
FK 506 appears to be of benefit in these conditions [33]. One patient with scleritis 
who was refractory to CsA has responded to FK 506. Preliminary data appear to 
show that steroid use will still be required in these conditions, although at a 
reduced dose. 
Psoriasis 
The results of treatment of psoriasis with FK 506 (n = 16) have been quite reward-
ing [21] (Fig. 7). All patients have shown a dramatic response to treatment, some 
with rapid clearing and others who take months to show clearing of the disease. 
Disease remission is associated with reduction in activated T cells within lesional 
skin (Fig. 8). The renal toxicity of the drug appears to limit the ability to achieve 
remissions in some patients, especially in those who have received prior treatment 
with methotrexate. Combination therapy may be required in some of these sub-
jects. 
Fig. 7 a, b. Appearance of patient with severe, recalcitrant , chronic plaque psoriasis a before and 
b 4 weeks after start of treatment with FK 506 
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Fig. 8a, b. EfTect of FK 506 treatment on psoriatic skin lesions. a IL-2 receptor et: (IL-2Ret:) 
chain-positive (CD25 +) lymphocytes within the upper dennis in untreated active disease and b 
absence of IL-2Ret:+ cells in lesional skin of the same patient, 4 weeks after start of systemic 
FK 506 therapy. Note also the marked reduction in epidermal keratinocyte proliferation 
Pyoderma gangrenosum 
The results of treat men t of pyoderma gangrenosum (n = 6) wi th FK 506 are 
promising [1]. One patient who was chronically steroid dependent since child-
hood, with multiple steroid-induced complications, was able to suspend the use 
of steroids for the first time in his life. Four out of six patients achieved total 
remissions and one significant partial remission was obtained. One patient was 
refractory to FK 506. 
Multiple sclerosis 
In the last few months, we have begun to treat patients (n = 57) with FK 506 and 
it is too early to make concrete statements. Patients with severe and mild disabil-
ities have been treated, so the group is heterogenous. Some patients who r,eceived 
FK 506 for transplants and who coincidentally, had multiple sclerosis, appear to 
have shown objective improvements over time. The neurotoxicity of the drug 
seems to be more limiting in this condition than in other autoimmune disorders. 
Type-J insulin-dependent diabetes 
To date, j 1 patients with new onset type-l diabetes have been treated with 
FK 506. Here we describe the experience with one case. 
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Fig. 9. The influence of FK 506 
therapy in a case of type-1 dia-
betes (described in the text). The 
figure shows serial results of a 
6 cajkg sustacal stimulation test 
(max 360 ml). Bloods were drawn 
at - 5, 0, 15, 30, 60, 120, 180, and 
300 min. The figure shows the 
basal and maximally stimulated 
C-peptide levels that reflect en-
dogenous insulin secretion over 
time after start of FK 506 treat-
ment. The patient is currently off 
insulin in a complete remission. 
o Basal; _ stimulated 
A 20-year-old male who was well until sustaining a cartilage injury to the right 
knee noted the sudden onset of polyuria, polydipsia and nocturia 1 day after the 
injury. There was no weight loss or blurred vision. He was noted to have glyco-
suria in the orthopedic surgeon's office and a blood sugar of 300 mg/l00 ml with 
ketonuria. He was started on 15 units of insulin daily and was referred to the 
UPMC autoimmune clinic for consideration in the FK 506 trial. The physical 
examination was unremarkable and the patient was started on FK 506 (10 mg 
twice daily). His HLA type was Al, A2, B8, B27, DR4 and islet cell antibodies 
were positive. 
A 6 calorie/kg Sustacal stimulation was done to assess endogenous C-peptide 
at trial entry and at 3-monthly intervals. The results of the stimulation tests 
performed over time are shown in Fig. 9. At 3 months, his insulin dose had 
decreased to 10 units/day. His glycosylated hemoglobin was 6.4% (normal up to 
6.4%). His starting creatinine was 1.0 and at 3 months was 1.2 mg/l00 mL with 
a glycosylated hemoglobin of 6.6%. His FK 506 dose was continued at 10 mg 
twice daily since he had no associated toxicities. Levels of FK 506 in serum were 
0.4-0.7 ng/ml. At 6 months, his insulin dose was 5 units/day. His serum crea-
tinine was 1.1 mg/lOO ml. His glycosylated hemoglobin was 6.6% and he had no 
toxicities. The FK 506 was continued. He was able to suspend the use of exoge-
nous insulin 8 months after entry and 6 weeks after suspending insulin, a 75 g oral 
glucose tolerance test showed impaired glucose tolerance (2-h plasma glucose 
285 mg/l00 ml) with no intervening value ~OMM mg/IOO ml. He is being main-
tained on 10 mg FK 506 twice daily with no toxicity. 
Nephrotic syndrome 
Our experience in treating steroid-resistant nephrotic syndrome (n = 32) with 
FK 506 monotherapy has demonstrated three distinct patterns [29, 30] (Fig. 10). 
These three groups are approximately equally divided. Some patients (e.g., pa-
tient no. 1 in Fig. 10) experienced a rapid reduction in proteinuria to essentially 
normal values within weeks of initiating therapy. Others (e.g., patient no. 2) 
responded partially to FK 506 alone, reducing protein excretion to approximate-
ly 50% of pretreatment values. The last group (e.g., patient no. 3) have demon-
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who showed a dramatic improvement in a renal function following the start of FK 506 therapy. 
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strated no change in protein excretion and have progressed to end-stage kidney 
disease. The majority of the patients treated to date have had focal sclerosing 
glomerulonephritis (GN) as the cause of steroid-resistant nephrotic syndrome. 
This, and the other histological lesions treated in our study, tend to be resistant 
to essentially all forms of therapy and tend to progress to end-stage renal disease. 
Previous studies have demonstrated elevated IL-2 and IL·2R levels in some 
forms of GN [22, 37]. Figure 11 illustrates the change in IL-2R in a patient (no. 1 
of Fig. 10), a 21 year old female with steroid resistant nephrotic syndrome, who 
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developed a complete remission of nephrotic syndrome and dramatic improve-
ment in renal function. The patient's proteinuria fell from 18000 mg/24 h to 
non-detectible levels within 3 months. IL-2R levels were elevated at all times 
relative to controls but fell with the introduction of FK 506. Although IL-2R 
levels rose slightly after 96 days of therapy, there was no associated increase in 
proteinuria or deterioration of renal function. This patient had, importantly, 
presented with a sudden onset of proteinuria which was treated within weeks of 
its perceived induction time. These three patterns of response may indicate vari-
ations in the basic pathogenesis of the disease in which cytokine production plays 
greater or lesser parts. Another possible explanation might be the existence of 
different pathogenic mechanisms in the induction and maintenance of the various 
forms of GN. Data from experimental Heymann's nephritis clearly suggest an 
evolution from a major involvement of T cells to later recruitment of other 
immune effector elements in the cascade illustrated in Fig. 2. Partial and total 
unresponsiveness to FK 506 may reflect that mediation of GN in these patients 
lies distal to IL-2 activation. In these cases, addition of other immunosuppressive 
agents which affect the more distal elements might improve the efficacy of 
FK 506. The use of anti-B cell agents, such as cyclophosphamide, would seem to 
be a rational choice, as would the use of small doses of prednisone in patients 
refractory to FK 506 alone. 
The nephrotoxicity of FK 506 has been the primary limiting factor in the 
treatment of these diseases. As with esA, FK 506 causes acute rises in serum 
creatinine which are dose dependent. There is improvement of renal function with 
dosage reduction. We have reduced the starting dose of FK 506 progressively 
from 0.15 mg/kg/day given twice to approximately one-third of this dose. 
Whether this approach will lessen the efficacy of FK 506 is yet to be determined. 
Table 6. Investigations on peripheral blood lymphocytes of autoimmune disease patients 
Quantitative flow cytometric immunophenotypic analysis 
One-color 
CD4 
CDS 
Two-color 
CD4: IL-2RIX; IL-2RP; 4B4 (helper-inducer); 2H4 (suppressor-inducer) 
CDS: IL-2RIX; IL-2RP 
Cytokine gene expression and cytokine production 
PCR analysis (mRNA) and ELISA (secreted protein) for: 
THl cytokines (IL-2; IFN-y) 
T H2 cytokines (IL-4; IL-l0) 
Proliferative responses 
Con A 
Anti-CD3 
rIL-2 
Relevant antigen (e.g., MBP, GAD) 
lL, Interleukin; PCR, polymerase chain reaction, ELISA, enzyme-linked immunosorbent assay; 
TH , T helper (cell). IFN, interferon; Con A, concanavalin A; r, recombinant; MBP, myelin basic 
protein; GAD, glutamic acid decarboxylase 
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We have seen no evidence of chronic FK 506 toxicity in any of the patients treated 
for nephrotic syndrome, even at the highest dose. 
Laboratory investigations to monitor the status of T H cells 
in FK 506-treated patients 
We are presently monitoring systemic CD4 + T cell activation status in autoim-
mune disease patients receiving FK 506 therapy. These studies are aimed at 
determining the influence of FK 506 on those markers of peripheral blood T cell 
function which may be affected by disease activity. In addition to quantitative 
one- and two-color immunofluorescence analysis for functional T cell subsets 
(Table 6), we are evaluating the influence of FK 506 treatment on cytokine gene 
expression by peripheral blood mononuclear cells and determining, where possi-
ble, proliferative responses of T cells to disease-associated antigens (e.g., myelin 
basic protein in multiple sclerosis). Representative preliminary results in patients 
with nephrotic syndrome and PBC (Fig. 12) show reductions both in CD4 + and 
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CDS + T cells expressing the IL-2R a chain (CD25), which is a functional marker 
of T cell activation, in response to FK 506 treatment. 
The side effects of FK 506 in humans 
Side effects of FK 506 and CsA observed both in transplant and autoimmune 
disease patients are shown in Table 7. Adverse effects associated with the use of 
FK 506 in transplant patients have recently been reviewed [13]. Adverse reactions 
requiring treatment or FK 506 dose reduction are impairment of renal function 
(due in part to decreased glomerular blood flow), alterations in glucose 
homeoastasis (a 15% incidence of new onset diabetes has been observed in 
FK 506-treated transplant patients but none in autoimmune disease patients) and 
Table 7. Side effects of FK 506 and esA 
Similarities 
Decreased glomerular blood flow 
Elevated serum postassium (? reduced aldosterone sensitivity of renal tubules) 
De novo hypertension (esA > FK 506) 
Lymphoproliferative disease a 
Nephrotoxicity 
Neurotoxicity 
Diabetogenicity 
Decreased bone mineralization b (in vitro) 
Steroid spearing (FK 506 > esA) 
Differences 
Hirsutism (esA; not FK 506) 
Gum hypertrophy (esA; not FK 506) 
Hyperlipidemia (esA) 
Hypocholesterolemia (FK 506) 
Elevated 1,25-(OH)2 DC levels (esA; not FK 506) 
a Reported in transplant patients 
b FK 506 data based on in vitro observations only 
c Serum, 1,25-dihydroxyvitamin D 
Table 8. Modes of action of new immunosuppressive drugs which offer opportunities for drug 
combination therapy in autoimmune disease 
Inhibitors of cytokine synthesis 
esA 
FK506 
Inhibitor of cytokine action 
Rapamycin 
Inhibitors of DNA synthesis 
Mizoribine 
Mycophenolic acid (RS61443) 
Brequinar sodium 
Inhibitors of cell maturation 
Dcoxyspergualin 
t purine synthesis 
t purine synthesis 
t pyrimidine synthesis 
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neurotoxicity. Amongst the benefits of FK 506 compared with CsA are a lower 
incidence of de novo hypertension, and the absence of gum hypertrophy and 
hirsutism. A 1.6% incidence of post-transplant lymphoproliferative disorders has 
been observed in UPMC FK 506-treated transplant patients. No lymphoprolifer-
ative disorders have been reported from the FK 506 treated autoimmune disease 
patient population (mean follow up time > 24 months). 
Prospects for drug combination therapies 
In addition to FK 506 mono therapy, the potential exists for drug combination 
therapies in autoimmune disease using FK 506 in combination with other novel 
(see Table 8) or well-established classes of immunosuppressive agents which act 
by mechanisms different from FK 506 or CsA. Experimental combination thera-
pies which are currently envisaged (e.g., for psoriasis or rheumatoid arthritis) 
include FK 506 together with an antiproliferative agent, such as methotrexate, 
cyclophosphamide or the purine biosynthesis inhibitor RS 61443 (mycophenolate 
mofetil). 
References 
1. Abu-Elmagd K, Jegasothy BY, Ackerman CD, Thomson AW, Rilo H, Nikolaidis N, et al. 
(1991) Efficacy of FK 506 in the treatment of recalcitrant pyoderma gangrenosum. Trans-
plant Proc 23: 3328 
2. Arita C, Hotokebuchi T, Miyahara H, Arai K, Sugioka Y, Takagishi K, Kaibara N (1990) 
Inhibition by FK 506 of established lesions of collagen-induced arthritis in rats. Clin Exp 
Immuno1832:456 
3. Baker BS. Fry L (1992) The immunology of psoriasis. Br J Dermatol 126: 1 
4. Canadian-European Randomized Control Trial Group (1988) Cyclosporin-induced remis-
sion of 100M after early intervention. Association of 1 year of cyc1osporin treatment with 
enhanced insulin secretion. Diabetes 37: 1574 
5. Carroll PB, Strasser S, Alejandro R (1991) The effect of FK 506 on cyclophosphamide-in-
duced diabetes in the NOD mouse model. Transplant Proc 23: 3348 
6. Castano L, Eisenbarth G L (1990) Type 1 diabetes: a chronic autoimmune disease of human, 
mouse and rat. Annu Rev Immunol 8:647 
7. Clark G, Williams DG (1992) Immunology of minimal-change nephropathy. In: Pusey P 
(ed) Immunology of renal diseases. Kluwer, Boston, pp 161 
8. Dohi K, Twano M, Muraguchi A, Horii Y, et al. (1991) The prognostic significance of 
urinary intcrleukin 6 in JgA nephropathy. Clin NephroJ 33: 1 
9. Firestein GS (1992) Mechanisms of tissue destruction and cellular activation in rheumatoid 
arthritis. Curr Opin Rheumatol 4: 348 
10. Flanagan WM, Corthesy B, Bram RJ, Crabtree GR (1991) Nuclear association of a T-cell 
transcription factor blocked by FK 506 and cyclosporin A. Nature 352:803 
11. Forrester JY (1991) Uveitis: pathogenesis. Lancet 338: 1498 
12. Fujino Y, Mochizuki M, Raber J, Kotake S, Gery I, Nussenblatt RB (1990) FK 506 treat-
ment of S-antigen induced uveitis in primates. Invest Ophthalmol Vis Sci 31:61 
13. Fung JJ, Alessiani M, Abu-Elmagd K, Todo S, Shapiro R, Tzakis A, et al (1991) Adverse 
effects associated with the use of FK 506. Transplant Proc 23: 3105 
14. Hanawa H, Kodama M, Zhang S, Izumi T, Shibata A (1992) An immunosuppressant com-
pound, FK 506, prevents the progression of autoimmune myocarditis in rats. Clin Immunol 
Immunopathol62:321 
FK 506 and autoimmune disease 343 
15. Hara S, Fukatsu A, Suzuki N, Sakamoto N, Matsuo S (1990) The effects of a new immuno-
suppressive agent, FK 506, on the glomerular injury in rats with accelerated nephrotoxic 
serum glomerulonephritis. Clin Immunol Immunopathol 57:351 
16. Hintzen RQ. Polman CH, Lucas Cl, van Lier RAW (1992) Multiple sclerosis: immunolog-
ical findings and possible implications for therapy. J Neuroimmunol 39: 1 
17. Hiraoka Y, Kishimoto C, Kurokawa M, Ochiai H, Sasayama S (1992) The effects of 
FK 506, a novel and potent immunosuppressant, upon murine coxsackievirus B3 myocardi-
tis. J Pharmacol Exp Ther 260: 1386 
18. Hisanaga S, Kawagoe H, Yamamoto Y, Kuroki N, Fujimoto S, Tanaka K, Kurokawa M 
(1990) Nephrotic syndrome associated with recombinant interleukin-2. Nephron 54:277 
19. Inamura N, Hashimoto M, Nakahara K, Nakajima Y, Nishio M, Aoki H, Yamaguchi I, 
Kohsaka M (1988) Immunosuppressive effect of FK 506 on experimental allergic en-
cephalomyelitis in rats. Int J Immunopharmacol 10:991 
20. Inamura N, Hashimoto M, Nakahara K, Aoki H, Damaguchi I, Kohsaka M (1988) Im-
munosuppressive effect of FK 506 on collagen-induced arthritis in rats. Clin lmmunol 
Immunopathol 46: 82 
21. legasothy BV, Ackerman CD, Todo S, Fung JJ, Abu-Elmagd K, Starzl TE (1992) 
Tacrolimus (FK 506) - A new therapeutic agent for severe psoriasis. Arch Dermatol128: 781 
22. 10rdan SC Querfeld U, Toyoda M, Prehn 1 (1990) Serum interleukin-2 levels in a patient 
with focal segmental glomerulosclerosis. Relationship to clinical course and cyclosporin A 
therapy. Pediatr Nephrol4:166 
23. Kawashima H, Fujino Y, Mochizuki M (1988) Effects of a new immunusuppressive agent, 
FK 506, on experimental autoimmune uveoretinitis in rats. Invest Ophthalmol Vis Sci 
23: 1265 
24. Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M, Kohsaka M, Aoki 
H, Imanaka H (1987) FK 506, a novel immunosuppressant isolated from a Streptomyces. 
I. Fermentation, isolation and physiochemical and biological characteristics. J Antibiot 
(Tokyo) 40: 1249 
25. Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T. Goto T, Okuhara M, 
Kohsaka M, Aoki H, Ochiai T (1987) FK 506, a novel immunosuppressant isolated from a 
Streptomyces. II. Immunosuppressive effect ofFK 506 in vitro. 1 Antibiot (Tokyo) 40: 1256 
26. Krawitt EL, Wiesner RH (1991) Autoimmune liver diseases. Raven Press, New York 
27. Liu 1, Farmer ID, Lane WS, Friedman J, Weissman I, Schreiber SL (1991) Calcineurin is a 
common target of cyclophilin-cyclosporin A and FKBP-FK 506 complexes. Cell 66: 807 
28. Matsukawa W, Hara S. Yoshida F, Suzuki N, Fukatsu A, Yuzawa Y, Sakamoto N. Matsuo 
S (1992) Effects of a new immunosuppressive agent, FK 506, in rats with active Heymann 
nephritis. 1 Lab Clin Med 119:116 
29. McCauley 1, Shapiro R, Scantlebury V, Gilboa N, et al (1991) FK 506 in the management 
of transplant related nephrotic syndrome and steroid resistant nephrotic syndrome. Trans-
plant Proc 23: 3354 
30. McCaulcy J, Shapiro R, Ellis D, Igdal H, et al (1993) A pilot trial of FK 506 in the 
management of steroid resistant nephrotic syndrome. Nephrol Dial Transplant (in press) 
31. Meingassner IG, Stutz A (1992) Immunosuppressive macrolides of the type FK 506: a novel 
class of topical agents for treatment of skin diseases? J Invest Dermatol 98:851 
32. Miyagawa .I, Yamamoto K, Hanafusa T, Itoh N, Nakagawa C Otsuka A, Katsura H, 
Yamagata K, Miyazaki A, Kono N, Tarui S (1990) Preventive effect of a new immunosup-
pressant FK 506 on insulinitis and diabetes in non-obese diabetic mice. Diabetologia 33: 503 
33. Mochizuki M, Masuda K, Sakane T, Inaba G, Ito K, Kogure M, et al (1991) A multi-centre 
clinical opcn trial of FK 506 in refractory uveitis, including Beh<;et's disease. Transplant 
Proc 23: 3343 
34. Mosmann TR, Coffman RL (1989) THl and TH2 cells: different patterns of lymphokine 
secretion lead to different functional properties. Annu Rev Immunol 7: 145 
35. Murase N, Lieberman I, Nalesnik M, Mintz D, Todo S, Drash AL, Starzl TE (1990) FK 506 
prevents spontaneous diabetes in the BB rat. Lancet IT: 373 
36. Nicoletti F, Meroni PL, Barcellini W, Grasso S, Borghi MO, Lunetta M, Di Marco R, 
Stefani S, Mughini L (1991) FK 506 prevents diabetes in diabetes-prone BB/Wor rats. 
Immunopharmacology 13: 1027 
344 A. W Thomson et al. 
37. Ohno I, Gomi H, Matsuda H, Nakano H, Matsumoto H, Kodama K (1991) Soluble IL-2 
receptor in patients with primary nephrotic syndrome. Nippon Jinzo Gakkai Shi 33:489 
38. Okuba Y, Tsukada Y, Maezawa A, Ono K, Ydano S, Naruse T (1990) FK 506, a novel 
immunosuppressive agent, induces antigen-specific immunotolerance in active Heymann's 
nephritis and in the autologous phase of Masugi nephritis. Clin Exp 1mmunol 82:450 
39. Roitt 1M, Hutchings PR, Dawe K1, Sumar N, Bodman KB, Cooke A (1992) The forces 
driving autoimmune disease. J Autoimmun 5 [Suppl A): 11 
40. Rose NR (1988) Current concepts of autoimmune disease. In: Kahan BD (cd) Cyclosporine. 
Applications in autoimmune diseases. Grune & Stratton, Philadelphia, pp 3 -1 0 
41. Sawada S, Suzuki G, Kawase Y, Takaku F (19R7) Novel immunosuppressive agent. FK 506. 
In vitro effects on the cloned T cell activation. J 1mmunol 139: 1797 
42. Schreiber SL, Crabtree GR (1992) The mechanism of action of cyclosporin A and FK 506. 
Immunol Today 13: 136 
43. Sigal NH, Dumont FJ (1992) Cyclosporin A, FK 506, and rapamycin: pharmacologic 
probes of lymphocyte signal transduction. Annu Rev Immunol 10: 519 
44. Starzl TE, Fung J, Venkataramanan R, Todo S, Demetris AJ, Jain A (1989) FK 506 for liver, 
kidney and pancreas transplantation. Lancet II: 1000 
45. Starzl TE, Todo S, Fung JJ, Groth C (cds) (1990) FK 506. A potential breakthrough in 
immunosuppression - clinical implications. Transplant Proc 22: 5 
46. Starzl TE, Thomson AW, Todo S, Fung JJ, Starzl TE (eds) (1991) Proceedings of the first 
international congress on FK 506. Transplant Proc 23:2709 
47. Takabayashi K. Koike T, Kurasawa K, Matsumura R, Sato T, Tomioka H, Ito I, Yoshiki 
T, Yoshida S (1989) Effect of FK 506, a novel immunosuppressive drug on murine systemic 
lupus erythematosus. Clin Immunol 1mmunopathol 51: 110 
48. Takagishi K, Yamamoto M, Nishimura A, Yamasaki G, Kanazawa N, Hotekebuchi T, 
Kaibara N (1989) Effects of FK 506 on collagen arthritis in mice. Transplant Proc 21: 1053 
49. Tamura K, Woo J, Murase N, Carrieri G, Nalesnik MA, Thomson AW (1993) Suppression 
of autoimmune thyroid disease by FK 506: influence on thyroid-infiltrating cells, adhesion 
molecule expression and anti-thyroglobulin antibody production. Clin Exp Immunol 91: 368 
50. Thomson AW (1989) FK 506. How much potential? 1mmunol Today 10:6-9 
51. Tocci MJ, Matkovich DA, Collier KA, Kwok P, Dumont F, Lin S, Degudicibus S, Siekierka 
JJ, Chin J, Hutchinson N1 (1989) The immunosuppressant FK 506 selectively inhibits ex-
pression of early T cell activation genes. J Immunol 143: 718 
52. von Graffenried B, Friend D, Shand N, Scheiss W, Timonen P (1989) Cyclosporin A 
(Sandimmun) in autoimmune diseases. In: Thomson AW (ed) Cyclosporin. Mode of action 
and clinical application. Kluwer, Boston, pp 213-251 
53. Wang SC, Zeevi A, Tweardy DJ, Jordan ML, Simmons RL (1991) FK 506, rapamycin and 
cyclosporine A: effects on IL-4 and IL-I0 mRNA levels in a T helper cell line. Transplant 
Proc 23:2920 
54. Wardle E (1991) Cytokine growth factors and glomerulonephritis. Nephron 57:257 
55. Yamamoto K, Mori A, Nakahama T, Ito M, Okudaira H, Miyamoto T (1988) Experimental 
treatment of autoimmune MRL/lprjlpr mice with immunosuppressive compound FK 506. 
Immunology 69: 222 
56. Zeevi A, Duquesnoy R, Eiras G, Rabinowich H, Todo S, Makowka L, Starzl TE (1987) 
Immunosuppressive effect of FK 506 on in vitro lymphocyte alloactivation: synergism with 
cyclosporine A. Transplant Proc 19 [Suppl 6]:40 
